Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028238425> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2028238425 endingPage "S39" @default.
- W2028238425 startingPage "S30" @default.
- W2028238425 abstract "A multicenter, 85-day, double-blind, randomized study was conducted to compare the effects of a single-dose and chronic inhalation of ipratropium bromide solution (500 micrograms) to the beta-adrenergic agonist metaproterenol (5% solution, 15 mg) in patients with chronic obstructive pulmonary disease (COPD). Patients were required to have a relatively stable, moderately severe COPD, forced expiratory volume in 1 second (FEV1) < 65% of predicted normal, FEV1 <70% of forced vital capacity (FVC), and a smoking history of > 10 pack-years. Following a 2-week baseline period, patients were randomized into either the ipratropium bromide (106 patients) or metaproterenol (107 patients) study groups. Pulmonary function testing was performed on days 1, 43, and 85. Secondary efficacy variables examined included peak expiratory flow rates, physician's global evaluation, quality of life, COPD symptom score, and use of concomitant medications. FEV1 was comparable between the two groups on day 1 (1.00 and 1.02 liters, ipratropium bromide vs metaproterenol, respectively; p = nonsignificant). The baseline FEV1 increased significantly in the ipratropium bromide group between day 1 and 43 by 10% (from 1.00 to 1.10 liters, p < 0.002) and remained 7% elevated on day 85 (1.07 liters) compared to day 1 (p < 0.02); it did not change in the metaproterenol group across all three test days. A clinically significant (> 15%) mean FEV1 response was observed on each of the 3 test days following drug inhalation in both treatment groups. The median duration of action was similar between groups (5 hours) on test day 1, but on day 85 the median duration for ipratropium bromide was r.5 hours compared to 3.0 hours for metaproterenol (p < 0.04). The secondary efficacy variables were uniformly better in the ipratropium bromide than the metaproterenol group. Side effects were infrequent and generally mild in both groups. These data suggest that the availability of a high-dose ipratropium bromide solution offers a safe and effective means of producing prolonged bronchodilation in patients with COPD." @default.
- W2028238425 created "2016-06-24" @default.
- W2028238425 creator A5019169162 @default.
- W2028238425 date "1996-01-01" @default.
- W2028238425 modified "2023-09-30" @default.
- W2028238425 title "A multicenter study of nebulized bronchodilator solutions in chronic obstructive pulmonary disease" @default.
- W2028238425 cites W1853608828 @default.
- W2028238425 cites W2006358545 @default.
- W2028238425 cites W2017694734 @default.
- W2028238425 cites W2044875769 @default.
- W2028238425 cites W2095270484 @default.
- W2028238425 cites W2131068365 @default.
- W2028238425 cites W2157690305 @default.
- W2028238425 cites W2175455493 @default.
- W2028238425 cites W4238017593 @default.
- W2028238425 cites W4243709722 @default.
- W2028238425 doi "https://doi.org/10.1016/s0002-9343(96)80061-1" @default.
- W2028238425 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8610715" @default.
- W2028238425 hasPublicationYear "1996" @default.
- W2028238425 type Work @default.
- W2028238425 sameAs 2028238425 @default.
- W2028238425 citedByCount "17" @default.
- W2028238425 countsByYear W20282384252012 @default.
- W2028238425 countsByYear W20282384252015 @default.
- W2028238425 countsByYear W20282384252022 @default.
- W2028238425 crossrefType "journal-article" @default.
- W2028238425 hasAuthorship W2028238425A5019169162 @default.
- W2028238425 hasConcept C126322002 @default.
- W2028238425 hasConcept C165637977 @default.
- W2028238425 hasConcept C2776042228 @default.
- W2028238425 hasConcept C2776780178 @default.
- W2028238425 hasConcept C2776954882 @default.
- W2028238425 hasConcept C2777714996 @default.
- W2028238425 hasConcept C2780532441 @default.
- W2028238425 hasConcept C2781018748 @default.
- W2028238425 hasConcept C3018587741 @default.
- W2028238425 hasConcept C42219234 @default.
- W2028238425 hasConcept C55520419 @default.
- W2028238425 hasConcept C71924100 @default.
- W2028238425 hasConcept C75603125 @default.
- W2028238425 hasConceptScore W2028238425C126322002 @default.
- W2028238425 hasConceptScore W2028238425C165637977 @default.
- W2028238425 hasConceptScore W2028238425C2776042228 @default.
- W2028238425 hasConceptScore W2028238425C2776780178 @default.
- W2028238425 hasConceptScore W2028238425C2776954882 @default.
- W2028238425 hasConceptScore W2028238425C2777714996 @default.
- W2028238425 hasConceptScore W2028238425C2780532441 @default.
- W2028238425 hasConceptScore W2028238425C2781018748 @default.
- W2028238425 hasConceptScore W2028238425C3018587741 @default.
- W2028238425 hasConceptScore W2028238425C42219234 @default.
- W2028238425 hasConceptScore W2028238425C55520419 @default.
- W2028238425 hasConceptScore W2028238425C71924100 @default.
- W2028238425 hasConceptScore W2028238425C75603125 @default.
- W2028238425 hasLocation W20282384251 @default.
- W2028238425 hasLocation W20282384252 @default.
- W2028238425 hasOpenAccess W2028238425 @default.
- W2028238425 hasPrimaryLocation W20282384251 @default.
- W2028238425 hasRelatedWork W173543370 @default.
- W2028238425 hasRelatedWork W1961645094 @default.
- W2028238425 hasRelatedWork W1975273780 @default.
- W2028238425 hasRelatedWork W1983444168 @default.
- W2028238425 hasRelatedWork W1988797668 @default.
- W2028238425 hasRelatedWork W1989635888 @default.
- W2028238425 hasRelatedWork W2132057205 @default.
- W2028238425 hasRelatedWork W2552894938 @default.
- W2028238425 hasRelatedWork W3172671402 @default.
- W2028238425 hasRelatedWork W2189486821 @default.
- W2028238425 hasVolume "100" @default.
- W2028238425 isParatext "false" @default.
- W2028238425 isRetracted "false" @default.
- W2028238425 magId "2028238425" @default.
- W2028238425 workType "article" @default.